Temasek leads $59 million Series B in biotech firm Just China

Temasek leads $59 million Series B in biotech firm Just China

Medicine, biotechnology, DNA, genetics and healthcare. Image: Pixabay

Hangzhou Just Biotherapeutics Co Ltd (Just China), an affiliate of Seattle-based Just Biotherapeutics, has closed a RMB400 million ($59 million) Series B round led by Singapore state investment firm Temasek Holdings, the China Money Network reported.

Others who participated in the round include Taikang Life Insurance Co., Ltd., Hangzhou Economic & Technological Development Area, Bank of China and Bank of Hangzhou. The biotech firm’s existing investors Lilly Asia Ventures and ARCH Venture Partners also made follow-on investments.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter